You are here

Fiasp, a Fast-Acting Mealtime Insulin, Receives FDA Approval

Novo Nordisk modifies NovoLog with niacinamide

A new formulation of insulin aspart injection (Fiasp, Novo Nordisk) has received FDA approval. Fiasp 100 units/mL is a fast-acting mealtime insulin indicated to improve glycemic control in adults with type-1 and type-2 diabetes.

Fiasp can be dosed at the beginning of a meal or within 20 minutes after starting a meal. It is a new formulation of NovoLog, in which the addition of niacinamide (vitamin B3) helps to increase the speed of the initial insulin absorption, resulting in an onset of appearance in the blood in approximately 2.5 minutes. Fiasp will be available in a pre-filled delivery device (FlexTouch pen) and a 10-mL vial.

Many adults with type-1 and type-2 diabetes struggle with blood sugar control after meals. As a result, many people with diabetes do not achieve their target A1C.

Fiasp will launch at the same list price as NovoLog and will be offered with a savings card program for eligible patients with commercial insurance to reduce co-pays. Fiasp will also be available to eligible patients through the Novo Nordisk Patient Assistance Program.

The approval of Fiasp is based on results from the onset phase 3a clinical development program. The clinical trials enrolled more than 2,000 adults with type-1 and type-2 diabetes to evaluate the efficacy and safety of Fiasp administered both at mealtime and after starting a meal.

Data from the trials showed that Fiasp demonstrated a reduction in A1C in adults with type-1 and type-2 diabetes. Common adverse reactions, excluding hypoglycemia, occurring in 5% or more of subjects included nasopharyngitis, upper respiratory tract infection, nausea, diarrhea, and back pain.

Source: Novo Nordisk; September 29, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks